Keymed Biosciences, Inc. (HK:2162) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Keymed Biosciences Inc. has announced that their Stapokibart injection, a treatment for chronic rhinosinusitis with nasal polyposis, has been included in the priority review and approval procedures by the Center for Drug Evaluation of China’s National Medical Products Administration. Stapokibart is the first IL-4R α antibody drug developed domestically in China and has demonstrated a promising safety profile and efficacy in prior clinical trials. However, the company cautions that there’s no guarantee of successful development or commercialization of the drug.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.